Adding resistance exercise to tirzepatide therapy reduced lean soft tissue mass loss and improved muscle strength in patients with overweight or obesity, without significantly altering weight or fat loss. Over 40 weeks, patients who were assigned to resistance exercise lost approximately 1.1 kg less lean soft tissue mass than those receiving tirzepatide alone.
The phase 3, single-center Tirzepatide and Resistance Exercise (T-REx) trial enrolled 120 adult men and postmenopausal women aged 50 to 70 years with obesity, or overweight with at least 1 weight-related comorbidity. Researchers randomly assigned 61 patients to tirzepatide alone and 59 to tirzepatide plus supervised resistance exercise 3 times weekly. All participants received tirzepatide for 40 weeks, with doses increased to a maximum of 15 mg weekly as tolerated. The exercise intervention consisted of progressive, supervised resistance training sessions lasting approximately 1 hour.
The co-primary outcomes were changes in total body fat mass and lean soft tissue mass, measured using dual-energy X-ray absorptiometry at baseline and every 8 weeks. Secondary outcomes included appendicular lean soft tissue mass, regional muscle strength, body mass index (BMI), waist circumference, and cardiovascular risk factors. Muscle strength was assessed using 1-repetition maximum testing for bench press, lat pulldown, and knee extension.
At week 40, total lean soft tissue mass declined by 4.67 kg in the tirzepatide-only group compared with 3.57 kg in the resistance exercise group, a statistically significant between-group difference of 1.09 kg. Appendicular lean soft tissue mass also declined less among patients assigned to resistance exercise, with losses of 2.92 kg vs 3.55 kg in those receiving tirzepatide alone, a between-group difference of 0.63 kg.
The trajectory of lean soft tissue mass loss was nonlinear. By week 24, total lean soft tissue mass had declined by 4.97 kg in the tirzepatide-only group and 3.64 kg in the exercise group. Losses subsequently plateaued, although appendicular lean soft tissue mass continued to decline throughout the intervention.
Muscle strength outcomes showed substantial differences between treatment groups. Patients receiving tirzepatide alone experienced declines of 4.09 kg in bench press strength, 4.42 kg in lat pulldown strength, and 4.42 kg in knee extension strength. In contrast, patients assigned to resistance exercise gained 4.68 kg, 8.58 kg, and 5.88 kg, respectively. The between-group differences in strength changes were 8.59 kg, 12.97 kg, and 9.78 kg across the 3 measures, all statistically significant.
Despite these differences in lean mass and strength, weight loss remained comparable between groups. Patients receiving tirzepatide alone lost 22.61 kg vs 22.28 kg among those assigned to resistance exercise. Total fat mass declined by 17.19 kg and 17.98 kg, respectively, without a statistically significant between-group difference. Both groups also experienced similar reductions in BMI and waist circumference.
Cardiometabolic improvements were comparable between groups. Systolic blood pressure decreased by approximately 15.3 mmHg with tirzepatide alone and 16.6 mmHg with combined treatment. Reductions in diastolic blood pressure, fasting glucose, insulin, glycated hemoglobin, total cholesterol, and triglycerides were also observed, without additional measurable benefits from resistance exercise.
Trial retention and adherence were high. Overall, 93% of patients completed the 40-week intervention, and mean adherence to resistance exercise sessions was 91%. Among the 111 patients who completed treatment, 78 received the maximum tirzepatide dose of 15 mg weekly.
Gastrointestinal adverse events were common in both groups. Nausea occurred in 55% of patients, while constipation, diarrhea, and indigestion were reported by approximately 29% to 36% of patients. Six serious adverse events occurred, none of which the authors considered related to tirzepatide or resistance exercise.
Sensitivity analyses adjusting for baseline BMI did not materially change the findings for total or appendicular lean soft tissue mass or regional muscle strength. A post hoc analysis of dietary records also found similar energy and protein intake between groups at baseline, week 24, and week 40.
The study's limitations included the use of dual-energy X-ray absorptiometry, which measures lean soft tissue mass rather than skeletal muscle mass directly, and some reductions in lean tissue may reflect changes in the nonfat components of adipose tissue during substantial weight loss. Additionally, participants were initially sedentary, middle-aged to older adults without diabetes or cardiovascular disease, which limited generalizability. The exercise intervention was closely supervised, and its feasibility in routine clinical practice remains uncertain. The open-label design also prevented complete blinding, and the 40-week follow-up did not establish whether differences in lean mass translate into improved long-term clinical outcomes.
“Resistance exercise training is an effective strategy to manage adverse impacts of incretin mimetic therapies and should be considered when prescribing incretin mimetics as anti-obesity therapy,” wrote lead study author Daniel J. Green, of the University of Western Australia, Perth, Australia, and colleagues.
Eli Lilly supplied tirzepatide but provided no additional trial funding and had no role in trial conduct. Several authors reported honoraria, advisory roles, grants, or financial interests involving pharmaceutical and nutrition companies. The remaining authors declared no competing interests.
Source: Nature Medicine
